Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 1, pp 61–65 | Cite as

A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients

  • Joseph P. Eder
  • Anthony D. Elias
  • Lois Ayash
  • Catherine A. Wheeler
  • Thomas C. Shea
  • Lowell E. Schnipper
  • Emil FreiIII
  • Karen H. Antman
Original Articles Cyclophosphamide, Continuous Infusion, Refractory Cancer

Summary

Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granulocytopenia of <500/μl that lasted for > 14 days or thrombocytopenia of <25,000/μl that lasted for > 14 days was the target dose-limiting toxicity in the absence of nonhematologic grade 4 toxicity. The maximal tolerated dose was 7 g/m2. Three patients died. Of 21 evaluable patients, 9 responded, including 8/9 who had experienced disease progression during prior oxazaphosphorine-containing combination chemotherapy. Clinically meaningful responses were observed in patients who had demonstrated clinical resistance to an oxazaphosphorine drug given at lower doses.

Keywords

Bone Marrow Cancer Patient Cyclophosphamide Thrombocytopenia Continuous Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antman KH, Griffin JD, Elias A, Socinski MA, Ryan LA, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE (1988) The effect of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) on chemotherapy induced myelosuppression. N Engl J Med 319: 593–598Google Scholar
  2. 2.
    Brock N (1983) The oxazaphosphorines. Cancer Treat Rev 10 [Suppl A]: 1–22Google Scholar
  3. 3.
    Brock N (1989) Oxazaphosphorine cytostatics: past-present-future. Cancer Res 49: 1–7Google Scholar
  4. 4.
    Brooke D, Bequette RJ, David RE (1973) Chemical stability of cyclophosphamide in parenteral solutions. Am J Hosp Pharm 30: 134–137Google Scholar
  5. 5.
    Bruce WR, Meeker BE, Valeriate FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245Google Scholar
  6. 6.
    Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Find DD, Neiman PE, Slichter SJ, Storb R, Thomas ED (1972) High dose cyclophosphamide therapy for malignant disease. Cancer 29: 357–365Google Scholar
  7. 7.
    Collins C, Mortimer J, Livingstone RB (1989) High dose cyclophosphamide in the therapy of refractory lymphomas and solid tumor malignancies. Cancer 63: 228–232Google Scholar
  8. 8.
    Cornbleet MA, Leonard RCF, Smyth JF (1984) High dose alkylating agent therapy: a review of clinical experiences. Cancer Drug Del 1: 227–238Google Scholar
  9. 9.
    Eder JP, Elias AD, Shea TC, Schryber SM, Teicher BA, Hung M, Burke J, Siegel R, Schnipper LE, Frei E III, Antman KH (1990) A phase I/II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8: 1239–1245Google Scholar
  10. 10.
    Frei E, Canellos GP (1980) Dose — a critical factor in cancer chemotherapy. Am J Med 69: 585–593Google Scholar
  11. 11.
    Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 141: 758–763Google Scholar
  12. 12.
    Griswald DP, Trader MW, Frei E III, Peters WP, Walpert MK, Laster WR (1987) Response of drug-sensitive and resistant L1210 leukemias to high dose chemotherapy. Cancer Res 47(9): 2323–2327Google Scholar
  13. 13.
    Johnson WW, Meadows DC (1971) Urinary-bladder fibrosis and telangiectasia associated with long term cyclophosphamide therapy. N Engl J Med 284: 290–294Google Scholar
  14. 14.
    Klein HO, Wickramanayake PD, Christian E, Coerper C (1984) Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Cancer 54: 1193–1203Google Scholar
  15. 15.
    Mills BA, Roberts RW (1979) Cyclophosphamide-induced cardiomyopathy. Cancer 43: 2223–2226Google Scholar
  16. 16.
    Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO (1988) High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376Google Scholar
  17. 17.
    Piver MS, Barlow JJ, Chung WS (1975) High dose cyclophosphamide (NSC-26 271) for recurrent of progressive ovarian adenocarcinoma. Cancer Chemother Rep 59: 1157–1159Google Scholar
  18. 18.
    Sladek NE, Doeden D, Powers JF, Krivitt W (1984) Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68: 1247–1254Google Scholar
  19. 19.
    Slavin RE, Millan JC, Mullins GM (1975) Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol 6: 693–709Google Scholar
  20. 20.
    Smith IE, Evans BD, Harland SJ (1983) High dose cyclophosphamide (7 g/m2) with or without autologous bone marrow rescuc after conventional chemotherapy in the treatment of patients with small cell lung cancer. Cancer Treat Rev 10 [Suppl A]: 79–81Google Scholar
  21. 21.
    Storb R, Buckner CD, Dillingham LA, Thomas ED (1970) Cyclophosphamide regimens in rhesus monkeys with and without marrow infusion. Cancer Res 30: 2195–2203Google Scholar
  22. 22.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E III (1989) Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 49: 5994–5998Google Scholar
  23. 23.
    Voelker G, Wagner T, Wientzek C, Hohorst H-J (1984) Pharmacokinetics of “activated” cyclophosphamide and therapeutic efficacies. Cancer 54: 1179–1186Google Scholar
  24. 24.
    Wagner T, Ehninger G (1987) Self-induction of cyclophosphamide and ifosfamide metabolism by repeated high-dose treatment. Contr Oncol 26: 69–75Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Joseph P. Eder
    • 1
    • 2
  • Anthony D. Elias
    • 3
  • Lois Ayash
    • 3
  • Catherine A. Wheeler
    • 1
  • Thomas C. Shea
    • 3
  • Lowell E. Schnipper
    • 1
  • Emil FreiIII
    • 3
  • Karen H. Antman
    • 3
  1. 1.The Department of MedicineBeth Israel HospitalBoston
  2. 2.Thorndike Laboratories of the Charles A. Dana Research InstituteBeth Israel HospitalBoston
  3. 3.Department of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston

Personalised recommendations